Late side effects of 3T MRI-guided 3D high-dose rate
brachytherapy of cervical cancer Institutional experiences

J 2019

Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences

VOJTISEK, R.; E. SUKOVSKA; J. BAXA; Marie BUDÍKOVÁ; P. KOVAROVA et al.

Základní údaje

Originální název

Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences

Autoři

VOJTISEK, R.; E. SUKOVSKA; J. BAXA; Marie BUDÍKOVÁ; P. KOVAROVA a J. FINEK

Vydání

STRAHLENTHERAPIE UND ONKOLOGIE, HEIDELBERG, SPRINGER HEIDELBERG, 2019, 0179-7158

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.899

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/19:00113450

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

Cervical cancer; 3D brachytherapy; Uterovaginal brachytherapy; 3T MRI-guided brachytherapy; Late side effects

Štítky

rivok

Změněno: 1. 4. 2020 11:48, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Purpose This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. Methods Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. Results The mean HR-CTV (high risk-clinical target volume) D-90 was 87 +/- 5.1 Gy equivalent dose corresponding to the conventional fractionation using 2Gy per fraction (EQD2, range 70.7-97.9Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2cm(rectum)(3)= 62.6 +/- 6.9Gy EQD2 (range 38.2-77.2Gy), D2cm(sigmoid)(3)= 66.2 +/- 6.8Gy EQD2 (43.2-78.6Gy) and D2cm(bladder)(3)= 75.1 +/- 8.3Gy EQD2 (58.2-92.6Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. Conclusion The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.

Citovat

VOJTISEK, R.; E. SUKOVSKA; J. BAXA; Marie BUDÍKOVÁ; P. KOVAROVA a J. FINEK. Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences. STRAHLENTHERAPIE UND ONKOLOGIE. HEIDELBERG: SPRINGER HEIDELBERG, 2019, roč. 195, č. 11, s. 972-981. ISSN 0179-7158. Dostupné z: https://doi.org/10.1007/s00066-019-01491-0.

@article{1641543,
   author = {Vojtisek, R. and Sukovska, E. and Baxa, J. and Budíková, Marie and Kovarova, P. and Finek, J.},
   article_location = {HEIDELBERG},
   article_number = {11},
   doi = {https://doi.org/10.1007/s00066-019-01491-0},
   keywords = {Cervical cancer; 3D brachytherapy; Uterovaginal brachytherapy; 3T MRI-guided brachytherapy; Late side effects},
   language = {eng},
   issn = {0179-7158},
   journal = {STRAHLENTHERAPIE UND ONKOLOGIE},
   title = {Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences},
   url = {https://link.springer.com/article/10.1007/s00066-019-01491-0},
   volume = {195},
   year = {2019}
}

TY  - JOUR
ID  - 1641543
AU  - Vojtisek, R. - Sukovska, E. - Baxa, J. - Budíková, Marie - Kovarova, P. - Finek, J.
PY  - 2019
TI  - Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences
JF  - STRAHLENTHERAPIE UND ONKOLOGIE
VL  - 195
IS  - 11
SP  - 972-981
EP  - 972-981
PB  - SPRINGER HEIDELBERG
SN  - 01797158
KW  - Cervical cancer
KW  - 3D brachytherapy
KW  - Uterovaginal brachytherapy
KW  - 3T MRI-guided brachytherapy
KW  - Late side effects
UR  - https://link.springer.com/article/10.1007/s00066-019-01491-0
L2  - https://link.springer.com/article/10.1007/s00066-019-01491-0
N2  - Purpose This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. Methods Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. Results The mean HR-CTV (high risk-clinical target volume) D-90 was 87 +/- 5.1 Gy equivalent dose corresponding to the conventional fractionation using 2Gy per fraction (EQD2, range 70.7-97.9Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2cm(rectum)(3)= 62.6 +/- 6.9Gy EQD2 (range 38.2-77.2Gy), D2cm(sigmoid)(3)= 66.2 +/- 6.8Gy EQD2 (43.2-78.6Gy) and D2cm(bladder)(3)= 75.1 +/- 8.3Gy EQD2 (58.2-92.6Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. Conclusion The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.
ER  -

VOJTISEK, R.; E. SUKOVSKA; J. BAXA; Marie BUDÍKOVÁ; P. KOVAROVA a J. FINEK. Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer Institutional experiences. \textit{STRAHLENTHERAPIE UND ONKOLOGIE}. HEIDELBERG: SPRINGER HEIDELBERG, 2019, roč.~195, č.~11, s.~972-981. ISSN~0179-7158. Dostupné z: https://doi.org/10.1007/s00066-019-01491-0.

Přehled o publikaci